Macrophage migration inhibitory factor and oral cancer

Journal of Oral Pathology and Medicine

Volumn 42, Issue 5, 2013, Pages 368-373

  França, Cristiane M ^a   Batista, Aline C ^b   Borra, Ricardo C ^c   Ventiades Flores, Jose A ^d   Mendonça, Elismauro F ^e   Deana, Alessandro M ^a   Mesquita Ferrari, Raquel A ^a   de Natali Caly, Decio ^a   de Mello Rode, Sigmar ^f   Faria, Miriam R ^g  

^a Nove de Julho University   (Brazil)

^b FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^c SÃO LEOPOLDO MANDIC INSTITUTE AND RESEARCH CENTER   (Brazil)

^d IBIRAPUERA UNIVERSITY   (Brazil)

^e Hospital Araujo Jorge   (Brazil)

^f SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^g UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Immunohistochemistry; Macrophage migration inhibitory factor; Mouth neoplasms; Oral cancer

Indexed keywords

MACROPHAGE MIGRATION INHIBITION FACTOR;

ADULT; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; LIP CANCER; MALE; MOUTH CANCER; PARENCHYMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL; TUMOR DIFFERENTIATION;

ALCOHOL DRINKING; CARCINOMA, SQUAMOUS CELL; CELL COUNT; COHORT STUDIES; EPITHELIUM; FEMALE; HUMANS; INFLAMMATION; KERATINS; LEUKOCYTES; LEUKOPLAKIA, ORAL; LIP NEOPLASMS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM GRADING; NEOPLASM STAGING; SMOKING; STROMAL CELLS; SURVIVAL RATE;

EID: 84876741447     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/jop.12011     Document Type: Article

References (32)

1. Bonifazi M, Malvezzi M, Bertuccio P, et al. Age-period-cohort analysis of oral cancer mortality in Europe: the end of an epidemic? Oral Oncol 2011; 47: 400-7.
2. Adair T, Hoy D, Dettrick Z, Lopez AD. Trends in oral, pharyngeal and oesophageal cancer mortality in Australia: the comparative importance of tobacco, alcohol and other risk factors. Aust N Z J Public Health 2011; 35: 212-9.
3. Chatenoud L, Bertuccio P, Bosetti C, et al. Trends in cancer mortality in Brazil, 1980-2004. Eur J Cancer Prev 2010; 19: 79-86.
4. Scully C. Oral cancer aetiopathogenesis; past, present and future aspects. Med Oral Patol Oral Cir Bucal 2011; 16: e306-11.
5. Bloom BR, Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 1966; 153: 80-2.
6. David JR. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci U S A 1966; 56: 72-7.
7. Calandra T, Bernhagen J, Metz CN, et al. MIF as a glucocorticoid-indeced modulator of cytokine production. Nature 1995; 377: 68-71.
8. Calandra T, Bernhagen J, Mitchell RA, Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994; 179: 1895-902.
9. Onodera S, Nishihira J, Iwabuchi K, et al. Macrophage migration inhibitory factor up regulates matrix metalloproteinase-9 and 13 in rat osteoblasts. Relevance to intracellular signaling pathways. J Biol Chem 2002; 277: 7865-74.
10. Honda A, Abe R, Makino T, et al. Interleukin-1b and macrophage migration inhibitory factor (MIF) in dermal fibroblasts mediate UVA-induced matrix metalloproteinase-1 expression. J Derm Sci 2008; 49: 63-72.
11. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immun 2003; 3: 791-800.
12. Larson DF, Horak K. Macrophage migration inhibitory factor: controller of systemic inflammation. Crit Care 2006; 10: 138.
13. Mitchell RA, Metz CN, Peng T, Bucala R. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phopholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem 1999; 274: 18100-6.
14. Mitchell RA. Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. Cell Signal 2004; 16: 13-9.
15. Xu X, Wang B, Ye C, et al. Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer. Cancer Lett 2008; 261: 147-57.
16. Meyer-Siegler KL, Iczkowski KA, Leng L, Bucala R, Vera PL. Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J Immunol 2006; 177: 8730-9.
17. He XX, Chen K, Yang J, et al. Macrophage migration inhibitory factor promotes colorectal cancer. Mol Med 2009; 15: 1-10.
18. Bach JP, Rinn B, Meyer B, Dodel R, Bacher M. Role of MIF in inflammation and tumorigenesis. Oncology 2008; 75: 127-33.
19. Shimizu T, Abe R, Nakamura H, Ohkawara A, Suzuki M, Nishihira J. High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem Biophys Res Commun 1999; 264: 751-8.
20. Ren Y, Tsui HT, Poon RT, et al. Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int J Cancer 2003; 107: 22-9.
21. Kamimura A, Kamachi M, Nishihira J, et al. Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung. Cancer 2000; 89: 334-41.
22. Dumitru CA, Gholaman H, Trellakis S, et al. Tumor-derived macrophage migration inhibitory factor modulates the biology of head and neck cancer cells via neutrophil activation. Int J Cancer 2011; 129: 859-69.
23. Lue H, Thiele M, Franz J, et al. Macrophage migration inhibitory factor promotes cell survival by activation of the AKT pathway and role for CSN5/JAB 1 in the control of autocrine MIF activity. Oncogene 2007; 26: 5046-59.
24. Anneroth G, Batsakis J, Luna M. Review of the literature and a recommended system of malignancy grading in oral squamous cell carcinomas. Scand J Dent Res 1987; 95: 229-49.
25. Kokko LL, Hurme S, Maula SM, et al. Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma. Oral Oncol 2011; 47: 510-6.
26. Suzuki F, Nakamaru Y, Oridate N, et al. Prognosticsignificance of cytoplasmic macrophage migration inhibitory factor expression in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy. Oncol Rep 2005; 13: 59-64.
27. Nemajerova A, Mena P, Fingerle-Rowson G, Moll UM, Petrenko O. Impaired DNA damage checkpoint response in MIF-deficient mice. EMBO J 2007; 26: 987-97.
28. Bernhagen J, Calandra T, Bucala R. The emerging role of MIF in septic shock and infection. Biotherapy 1994; 8: 123-7.
29. Ferreira FO, Ribeiro FL, Batista AC, Leles CR, de Cássia Gonçalves Alencar R, Silva TA. Association of CCL2 with lymph node metastasis and macrophage infiltration in oral cavity and lip squamous cell carcinoma. Tumour Biol 2008; 29: 114-21.
30. Zancope E, Costa NL, Junqueira-Kipnis AP, et al. Differential infiltration of CD8+ and NK cells in lip and oral cavity squamous cell carcinoma. J Oral Pathol Med 2010; 39: 162-7.
31. Xia HH, Yang Y, Chu KM, et al. Serum macrophage migration-inhibitory factor as a diagnostic and prog-nostic biomarker for gastric cancer. Cancer 2009; 115: 5441-9.
32. Verjans E, Noetzel E, Bektas N, et al. Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer. BMC Cancer 2009; 9: 230-4.